MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Articles

Pharmalicensing brings you advice, commentary and analysis from industry experts.

Articles

Displaying 1..10 of 17 - per page Next page
Order by
Clinical diagnosis forms the basis for any better therapeutic outcomes. Though effective drugs hold the key, timely and accurate diagnosis forms the corner stone in the treatment of any pathological condition. More
Globally 10.0 million new cases of cancer are registered each year. Rising incidence of cancer warrants equally high treatment costs. The cancer market is posing exorbitantly high expenditures to the governments. More
Pharmalicensing: A shop window for opportunities in the biotechnology industry More
'High market penetration and top service,' Dr Anders Holmberg, Managing Director Dextech Medical, summarizes Pharmalicensing More
What used to be a relatively esoteric line of research - immunotherapy for cancer -- has become mainstream. More
In the 12-month period to the end of June 2005, according to IMS, the global benign prostatic hypertrophy/hyperplasia (BPH) treatment market (G4C ATC therapy class) was worth almost $4 billion and grew by 12% in fixed-rate US dollar terms. More
Cancer has become one of the most significant causes of morbidity and mortality in the world, and recently overtook heart disease as the leading cause of death for Americans. More
Most members of the public have probably never even heard of basal cell carcinoma (BCC), or 'rodent ulcer' - yet it is the commonest of all cancers. Here is an in depth look at Basal cell carcinoma. More
The development of new, targeted therapies is prolonging the life of cancer patients and increasing the growth of the market for oncology drugs. More
Harren Jhoti discusses the progress Astex has made using a chemistry based approach to drug design. More
Displaying 1..10 of 17 - per page Next page
Order by

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioPartnering America
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us